BINEX Co. Ltd
BINEX Co., Ltd. operates as a pharmaceutical company in South Korea. It offers bisroot products; GI tract and antispasmodic, and antiulcer agents; NSAIDs; cardiovascular and urology products; hepatic protectors; ointments and creams; ophthalmic solutions; CNS agents; digestive products; constipation and blood circulation products; antibiotic and antifungal agents; cough and cold remedy products; … Read more
BINEX Co. Ltd (053030) - Net Assets
Latest net assets as of September 2025: ₩187.21 Billion KRW
Based on the latest financial reports, BINEX Co. Ltd (053030) has net assets worth ₩187.21 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩304.35 Billion) and total liabilities (₩117.14 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩187.21 Billion |
| % of Total Assets | 61.51% |
| Annual Growth Rate | 13.96% |
| 5-Year Change | 4.84% |
| 10-Year Change | 25.99% |
| Growth Volatility | 36.28 |
BINEX Co. Ltd - Net Assets Trend (2004–2024)
This chart illustrates how BINEX Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BINEX Co. Ltd (2004–2024)
The table below shows the annual net assets of BINEX Co. Ltd from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩181.61 Billion | +0.16% |
| 2023-12-31 | ₩181.33 Billion | -5.37% |
| 2022-12-31 | ₩191.61 Billion | +6.20% |
| 2021-12-31 | ₩180.42 Billion | +4.16% |
| 2020-12-31 | ₩173.22 Billion | +7.93% |
| 2019-12-31 | ₩160.50 Billion | +7.40% |
| 2018-12-31 | ₩149.43 Billion | +16.06% |
| 2017-12-31 | ₩128.75 Billion | -8.39% |
| 2016-12-31 | ₩140.55 Billion | -2.49% |
| 2015-12-31 | ₩144.14 Billion | +47.92% |
| 2013-12-31 | ₩97.45 Billion | +6.04% |
| 2012-12-31 | ₩91.90 Billion | +30.20% |
| 2011-12-31 | ₩70.58 Billion | +104.60% |
| 2007-12-31 | ₩34.50 Billion | +8.12% |
| 2006-12-31 | ₩31.91 Billion | +10.08% |
| 2005-12-31 | ₩28.99 Billion | +117.64% |
| 2004-12-31 | ₩13.32 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to BINEX Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 278.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩20.71 Billion | 11.42% |
| Common Stock | ₩16.34 Billion | 9.01% |
| Other Components | ₩144.31 Billion | 79.57% |
| Total Equity | ₩181.36 Billion | 100.00% |
BINEX Co. Ltd Competitors by Market Cap
The table below lists competitors of BINEX Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangzhou Newlife New Material Co. Ltd. A
SHE:301323
|
$253.79 Million |
|
Compagnie du Bois Sauvage SA
BR:COMB
|
$253.83 Million |
|
SANDUR MANGANESE AND IRON ORES LTD
NSE:SANDUMA
|
$254.18 Million |
|
First of Long Island Corp
NASDAQ:FLIC
|
$254.21 Million |
|
Aspen Aerogels Inc
NYSE:ASPN
|
$253.70 Million |
|
Hidrovias do Brasil S.A
SA:HBSA3
|
$253.61 Million |
|
Jilin Jlu Communication Design Institute Co Ltd
SHE:300597
|
$253.56 Million |
|
Beijing Seeyon Internet Software Cp
SHG:688369
|
$253.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BINEX Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 181,307,526,610 to 181,361,189,120, a change of 53,662,510 (0.0%).
- Net loss of 35,070,820,730 reduced equity.
- Other factors increased equity by 35,124,483,240.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-35.07 Billion | -19.34% |
| Other Changes | ₩35.12 Billion | +19.37% |
| Total Change | ₩- | 0.03% |
Book Value vs Market Value Analysis
This analysis compares BINEX Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.08x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.67x to 2.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩4571.44 | ₩12220.00 | x |
| 2017-12-31 | ₩4186.34 | ₩12220.00 | x |
| 2018-12-31 | ₩4792.96 | ₩12220.00 | x |
| 2019-12-31 | ₩5146.11 | ₩12220.00 | x |
| 2020-12-31 | ₩5552.18 | ₩12220.00 | x |
| 2021-12-31 | ₩5834.14 | ₩12220.00 | x |
| 2022-12-31 | ₩6195.91 | ₩12220.00 | x |
| 2023-12-31 | ₩5862.90 | ₩12220.00 | x |
| 2024-12-31 | ₩5864.64 | ₩12220.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BINEX Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -26.97%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 1.54x
- Recent ROE (-19.34%) is below the historical average (2.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 10.84% | 7.76% | 0.50x | 2.81x | ₩94.82 Million |
| 2005 | 9.18% | 8.16% | 0.71x | 1.60x | ₩-217.74 Million |
| 2006 | 10.30% | 8.62% | 0.75x | 1.59x | ₩85.71 Million |
| 2007 | 9.50% | 8.28% | 0.73x | 1.56x | ₩-157.04 Million |
| 2011 | 4.93% | 6.33% | 0.53x | 1.47x | ₩-3.48 Billion |
| 2013 | -4.20% | -7.10% | 0.47x | 1.26x | ₩-13.75 Billion |
| 2015 | -6.44% | -13.96% | 0.38x | 1.22x | ₩-23.70 Billion |
| 2016 | -2.14% | -3.71% | 0.46x | 1.26x | ₩-17.06 Billion |
| 2017 | -8.77% | -14.48% | 0.47x | 1.30x | ₩-24.17 Billion |
| 2018 | 4.24% | 6.09% | 0.55x | 1.27x | ₩-8.61 Billion |
| 2019 | 5.30% | 6.79% | 0.62x | 1.26x | ₩-7.55 Billion |
| 2020 | 3.70% | 4.82% | 0.49x | 1.56x | ₩-10.91 Billion |
| 2021 | 10.58% | 14.21% | 0.49x | 1.51x | ₩1.05 Billion |
| 2022 | 6.49% | 7.94% | 0.53x | 1.56x | ₩-6.72 Billion |
| 2023 | 2.58% | 3.02% | 0.60x | 1.42x | ₩-13.46 Billion |
| 2024 | -19.34% | -26.97% | 0.47x | 1.54x | ₩-53.21 Billion |
Industry Comparison
This section compares BINEX Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $96,196,506,488
- Average return on equity (ROE) among peers: -9.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BINEX Co. Ltd (053030) | ₩187.21 Billion | 10.84% | 0.63x | $253.78 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.69 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $94.65 Billion | 9.66% | 0.53x | $57.77 Million |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $37.82 Million |
| Sam-A Pharm. Co. Ltd (009300) | $148.92 Billion | 6.63% | 0.09x | $21.27 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $257.20 Billion | 4.73% | 0.21x | $50.06 Million |
| WooGene B&G Co. Ltd (018620) | $26.51 Billion | -25.02% | 1.26x | $10.61 Million |
| Oscotec Inc (039200) | $28.83 Billion | -91.10% | 0.70x | $890.75 Million |
| EstechPharma Co. Ltd (041910) | $123.30 Billion | 5.58% | 0.09x | $50.99 Million |
| Komipharm International Co. Ltd (041960) | $93.39 Billion | -15.32% | 0.50x | $237.27 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $40.83 Billion | 8.91% | 0.29x | $20.48 Million |